A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Brexpiprazole (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 21 Jun 2019 Planned End Date changed from 1 Apr 2020 to 1 Nov 2021.
- 21 Jun 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Nov 2021.
- 08 Oct 2018 Planned number of patients changed from 387 to 480.